Pleural Effusion, Malignant Clinical Trial
Official title:
Intrapleural Hypertonic Cisplatin Treatment for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer.
To assess the effect and toxicity of intrapleural administration of hypertonic cisplatin for malignant pleural effusion in patients with non-small-cell lung cancer.
The lung was fully expanded by a thoracostomy using a chest tube with a double lumen, and then the patients were enrolled into the trial.First, premedication including antiemetics and hydration were performed. Thereafter, 75 mg of body surface area of cisplatin in 50 ml of distilled water was injected through a chest tube.The patients were asked to change position (supine and bilateral decubital) from time to time for 30 minutes. The chest tube was clamped for 48 h and then the tube was declamped and allowed to drain. When the drainage effusion was less than 100 ml a day, the chest tube was removed. Any patient whose drainage effusion continued for over 2 weeks was withdrawn from the trial and was also judged to be a nonresponder. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05693727 -
Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion
|
||
| Recruiting |
NCT05910112 -
Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
|
||
| Completed |
NCT03270215 -
The Added Value of CT Scanning in Patients With an Unilateral Pleural Effusion
|
||
| Completed |
NCT03272997 -
The Value of PET-CT in Pleural Effusions
|
||
| Completed |
NCT00099541 -
Non-small Cell Lung Cancer Registry
|
Phase 4 | |
| Recruiting |
NCT04844827 -
Pleural Carcinomatosis Tissue Banking
|
||
| Not yet recruiting |
NCT06436807 -
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
|
||
| Recruiting |
NCT05278975 -
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
|
Phase 1/Phase 2 | |
| Terminated |
NCT00316134 -
Multiple Biomarkers in Undiagnosed Pleural Effusion
|
N/A | |
| Not yet recruiting |
NCT06275178 -
Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study
|
||
| Recruiting |
NCT04684459 -
Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis
|
Early Phase 1 | |
| Recruiting |
NCT04670562 -
Longitudinal Follow up of Patients With Pleural Effusion
|
||
| Not yet recruiting |
NCT02805062 -
Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy
|
N/A | |
| Completed |
NCT03276715 -
Prognostic Factors on Malignant Pleural Effusion
|
||
| Completed |
NCT03394105 -
Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Terminated |
NCT02702700 -
Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
|
Phase 1 | |
| Recruiting |
NCT02045121 -
Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management
|
N/A | |
| Completed |
NCT01670786 -
Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion
|
Phase 4 | |
| Active, not recruiting |
NCT05077111 -
A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia
|
Phase 4 |